This study aimed to compare the real-life results of TECAM, a thiotepa-based conditioning regimen consisting of thiotepa (40 mg/m 2 days − 5 to − 2), etoposide (200 mg/m 2 days − 6 to − 3), cytarabine (200 mg/m 2 days − 4 to − 1), cyclophosphamide (60 mg/kg day − 3), and melphalan (60 mg/m 2 days − 2 to − 1) with that of the conventional carmustine-based regimen BEAM. We reviewed 125 consecutive patients who underwent a first autologous transplantation (ASCT) for B-cell lymphomas at a large tertiary transplantation center between 1999 and 2014. TECAM (n = 65) and BEAM (n = 60) had comparable results (3yPFS 49 vs 62%, P = 0.16; 3yOS 64 vs 71%, P = 0.44; TRM 1.6 vs 5%, P = 0.35) without a difference in toxicity or time to engraftment. Notably, comparable outcomes were observed even though patients treated with TECAM were older (55 vs 44) and had a trend towards more prior lines of therapy (42 prior lines: 43 vs 27%, P = 0.08). In this regard, 23% of TECAM patients were over the age of 65 yet could withstand therapy with similar results to younger patients. We conclude that, replacing carmustine by thiotepa and cyclophosphamide for ASCT conditioning, has comparable efficacy and safety profiles with a possible advantage in older patients.
INTRODUCTION
Autologous hematopoietic stem cell transplantation (ASCT) has become the cornerstone of treatment for relapsed and refractory lymphomas. 1 However, treatment-related toxicities prevent many patients gaining the benefits of this procedure, and suboptimal results remain a serious concern. [2] [3] [4] [5] Reduction in treatment toxicities while achieving good transplantation outcomes will allow more patients to undergo this procedure with a potential for long-term remission or cure.
An appropriate conditioning regimen should demonstrate a clear efficacy against relapsed lymphoma; it should contain chemotherapeutic agents that have not been previously administered; and should have manageable toxicities. 5 Over the past decades several such regimens have been developed, of which the most widely accepted are those based on a carmustine backbone, BEAM (carmustine, etoposide, cytarabine and melphalan) and CBV (cyclophosphamide, carmustine and etoposide). 4 However,~40% of patients treated with these regimens will either relapse or die within 3 years of transplantation, with 4-7% dying from transplant-related complications. [4] [5] [6] Several alternative regimens have been suggested in an attempt to replace carmustine with agents thought to be less toxic. 4, 7 Thiotepa is an alkylating agent commonly used in high-dose therapy and ASCT, particularly in central nervous system lymphoma. 8 It has been shown to produce comparable results when substituted for carmustine in the BEAM regimen (that is, TEAM regimen). 9 In our institution we have been using a similar regimen replacing carmustine with thiotepa and cyclophosphamide (that is, TECAM). 10 Though never formally tested, it was our team's impression that this protocol was less toxic than BEAM, and it was therefore administered to patients considered too frail to withstand the latter. This study aimed to compare the outcomes of BEAM and TECAM in patients transplanted for relapsed or refractory Hodgkin's and nonHodgkin's B-cell lymphomas at our institution.
SUBJECTS AND METHODS

Patients and treatment
In this retrospective study, we reviewed the data from all patients who underwent ASCT for B-cell lymphomas at a large tertiary transplantation center between October 1999 and January 2014. All patients were treated with either the TECAM regimen consisting of thiotepa (40 mg/m 2 days − 5 to − 2), etoposide (200 mg/m 2 days − 6 to − 3), cytarabine (200 mg/m 2 days − 4 to − 1), cyclophosphamide (60 mg/kg day − 3), and melphalan (60 mg/ m 2 days − 2 to − 1) or the BEAM regimen consisting of carmustine (300 mg/m 2 IV day − 7), etoposide (200 mg/m 2 days − 6 to − 3), cytarabine (200 mg/m 2 days − 6 to − 3), and melphalan (140 mg/m 2 day − 2). Posttransplant growth factor (G-CSF) administration was not routine and given per local policy to patients with a severe infection during the neutropenic phase, elderly patients who received grafts with 'low' CD34+ cell numbers, and in cases with late or slow engraftment beyond day +14. Regimens were not randomized. TECAM was used as the standard conditioning regimen between 1999 and 2006. From 2007, it was replaced by BEAM and was administered per physician discretion to patients who were considered too old or too frail to withstand BEAM. Patients were excluded if they had previously undergone an ASCT or if meaningful data were lacking. All cases were reported to the European Bone Marrow Transplantation (EBMT) registry in accordance with reporting guidelines. Data were extracted from the electronic health records and the 
Response assessment and outcome measures
Disease assessment was performed prior to transplant, and at three months intervals for the first 2 years post-transplant, and at 6 months intervals thereafter. Disease response was defined according to standard lymphoma response criteria. 11 Neutrophil engraftment was defined as the first of three consecutive days with a neutrophil count4500 cell/μL and platelet engraftment as the first of three consecutive days with unsupported platelets count ⩾ 20 000 cells/μL. Length of stay was defined as the time from admission for transplantation until discharge. We extracted data about severe complications including presence of severe mucositis, documented bacteremia or fungemia, hepatotoxicity and mechanical ventilation. Severe mucositis was defined as any grade 4 mucositis per the World Health Organization criteria. 16 Treatment-related mortality (TRM) was defined as non-relapse death within 100 days from transplantation. Overall and progression free survival (OS, PFS) were defined from the time of stem cell infusion until death from any cause, relapse (for PFS) or end of follow-up. Cases were censored at 48 months to correct for the longer follow-up in the TECAM group.
Statistical analysis
To compare baseline characteristics between the TECAM and BEAM arms we used the Fisher's exact test for categorical variables, the Student's t-test for normally distributed variables; and the Mann-Whitney test for non-normally distributed variables. Median follow-up was calculated using the reverse Kaplan-Meier method. Survival analyses were performed using Kaplan-Meier plots and differences between the groups were evaluated with the log-rank test. We performed multivariable survival analyses using the Cox proportional hazard method adjusting the number of variables in the model to the number of events (expanded models with all variables are presented in the supplement). 12 Statistical significance was defined as α ⩽ 0.05 (double sided). Analyses were carried out using R v. 3.01 (R foundation, Vienna, Austria).
RESULTS
A total of 125 patients (60 treated with BEAM and 65 treated with TECAM) were included in the study (Table 1) . Patients treated with TECAM were over 11 years older (median age at transplantation 55.0 vs 43.5, P = 0.001), but there was no difference in comorbidity burden between the groups (median HCTCI 2.0 for both groups, P = 0.26; HCTCI ⩾ 3 in 20% n = 12 TECAM vs 11% n = 6 BEAM, P = 0.25). Of note, 52% (n = 34) of TECAM patients were transplanted between 1999 and 2006, before BEAM became the standard conditioning regimen at the department. Compared to patients transplanted prior to 2007, patients receiving TECAM in the ensuing years were older (61 vs 52 years, P = 0.06) and had slightly more comorbidities (median HCTCI 2.0 vs 1.0, P = 0.07; HCTCI ⩾ 3 in 24% n = 7 vs 16% n = 5, P = 0.65; Supplementary Table 1) .
Groups were similar in terms of patient mix with 46% (n = 58) of patients transplanted for DLBCL, 34% (n = 42) for HL and the reminder for other B-cell lymphomas. TECAM patients had a longer time interval from first diagnosis to transplant (23 vs 15 months, P = 0.001) and marginally more previous lines of therapy (42 lines, 43% TECAM vs 27% BEAM, P = 0.08). However, there was no difference in the rate of refractoriness before transplantation (28%, n = 18 TECAM vs 27%, n = 16 BEAM, P = 0.9). Notably, in terms of conditioning regimen, 20% (n = 13) of TECAM patients had a dose reduction of a median of 15% (range 10-30%) as opposed to a single patient in the BEAM arm. Further, 17% (n = 11) of TECAM patients received a graft of o 2 × 10 6 CD34+ cells/kg as opposed to a single patient in the BEAM group (P = 0.01).
Median length of stay was 25 days in the TECAM arm and 24 days in the BEAM arm (P = 0.23). Median time to neutrophil and platelet engraftment was similar in both groups (11 vs 11 days for neutrophil engraftment, P = 0.44; and 13 vs 13 days for platelet engraftment, P = 0.67). There was no difference in the requirement for blood products or in the rate of severe mucositis, bacteremia/ fungemia or mechanical ventilation (Table 2) . Pulmonary toxicities were relatively rare. Overall, seven patients required mechanical ventilation and two had pleural infiltrates, which resolved without any invasive intervention. There were four patients with treatment-related pneumonitis (2 BEAM and 2 TECAM), all of whom requiring mechanical ventilation.
Median follow-up was 47 months (95% CI 37-48) with 40 deaths occurring during that time, 30 due to disease progression or relapse, five due to infections of which four where TRM, and seven undocumented cause of death. Median OS for the latter seven patients was 20 m (range 14-47). An additional 13 patients experienced a relapse but were alive at the end of follow-up. In univariable analyses TECAM was associated with a shorter PFS, but this was not statistically significant (3yPFS 49%, 95% CI 38-64% TECAM vs 62%, 95% CI 50-77% BEAM, P = 0.16; Figure 1 ). There was no difference in OS (3yOS 64%, 95% CI 53-74%, TECAM vs 71%, 95% CI 59-85%, BEAM, P = 0.44; Figure 2 ) or in the rate of TRM (1.6% n = 1 TECAM vs 5% n = 3 BEAM, P = 0.35). The only other factor associated with OS in univariable analyses was refractoriness to salvage chemotherapy prior to conditioning (OR 2.4 95% CI 1.2-4.9, P = 0.02; Table 3 ). Notably, dose reductions of TECAM, though observed more among older patients, did not have a significant effect on the survival analysis (Supplementary Table 3 and Supplementary Figure 1) In multivariable analysis including conditioning regimen, age at transplant, lymphoma subtype, and disease status at transplant there was no association between conditioning regimen and PFS (P = 0.14) or OS (P = 0.59). The only factor found to be associated with survival was the depth of response following the procedure (Table 4; Supplementary Table 2) .
Interestingly, older age was not associated with a shorter survival in any of the analyses. There were 22 patients 65 years or older (median 69; range 65-75) in the TECAM group and 6 (median 66; range 65-68) in the BEAM group (Supplementary  Table 3 ). Median OS for these patients was 47 months TECAM and 34 months BEAM (Supplementary Table 4 ; samples too small to 
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allow meaningful statistical analysis). Notably, there were no deaths noted during the peri-transplant period in either group (TRM 0%).
DISCUSSION
This study aimed to compare the real-life results of a thiotepabased conditioning regimen for ASCT (TECAM) with that of the conventional carmustine-based regimen (BEAM). Overall patients treated with TECAM had shorter PFS and OS (3yPFS 47 vs 59%; 3yOS 61% vs 67%) but these differences were not statistically significant. Further, there was no difference in toxicity profile or time to engraftment. Notably, these comparable outcomes were even though patients treated with TECAM were, on average, 11.5 years older, had a trend toward more prior lines of therapy, increased time from original diagnosis, and were possibly frailer as marked by a considerably higher rate of dose reductions in this group. In this regard, 23% (n = 16) of TECAM patients were over the age of 65 (median 70; range 65-75) yet could withstand therapy with comparable results to younger patients. Our results are in keeping with those previously reported in the literature. In a large retrospective study including 1730 BEAM transplants for non-Hodgkin's B-cell lymphomas reported to the CIBMTR, 3yPFS was 51%, 3y OS was 64% and 1y TRM was 4%. 4 A recent EBMT analysis of 535 patients treated with various thiotepa-based regimens as compared to BEAM, presented similar treatment outcomes with no difference noted between regimens including in subset analyses by lymphoma subtype. 9 In a subset analysis of that study, focusing on the matched-pair comparison of TEAM (n = 100) to BEAM (n = 199), 30mPFS was 49 vs 62%, 30mOS 77% for both groups and relapse incidence 50 vs 37% (TEAM vs BEAM, respectively, all differences statistically insignificant). 9 Notably in that cohort patients were considerably younger than in our study (median age 44 vs 55 years), there was a higher proportion of Hodgkin's lymphoma (46% vs 25%) and a shorter median follow-up time (18 vs 47 months). Another regimen TECA (thiotepa, etoposide and carboplatin) was reported in a single arm retrospective study to achieve 5yOS of 78% in HL (n = 58) and 71% in NHL (n = 45). 13, 14 Here, too, median age was younger than in our cohort (39-43 years), but the NHL group included a high proportion of peripheral T cell lymphoma (40%, n = 18).
14 Finally, a recent report of conditioning with thiotepa, etoposide and cyclophosphamide in 42 NHL patients demonstrated a 5yPFS of 53% and a 5yOS of 73%. 15 Interestingly, this regimen included considerably higher doses of thiotepa and etoposide than TECAM or TEAM, yet was well tolerated in a patient population which included older patients (median age 55 years). Other reports of thiotepa-based regimens include TMJ (thiotepa, Figure 1 . Progression free survival by conditioning regimen.
Thiotepa-cyclophosphamide-EAM vs BEAM for ASCT E Joffe et al mitoxantrone and carboplatin) which, in a single center retrospective report, was demonstrated to achieve a 5yPFS 43%, and BuMelTT (busulfan, melphalan and thiotepa) with an approximate 3yPFS of 50%. However, both regimens were associated with considerable cardiac, pulmonary and hepatic toxicities. [16] [17] [18] Notably, the feared pulmonary toxicity of carmustine is mainly seen in regimens containing cyclophosphamide while in large series of patients treated with BEAM it has only been reported in 0-3%. 4, 9 Finally, several recent studies evaluated modifications of the BEAM regimen, replacing carmustine with alternative agents. 19 Notable, was a phase I/II study using bendamustine (BeEAM) conditioning in 43 patients with R/R lymphoma, demonstrating an impressive 3yPFS of 72% and no TRM. 20 Several recent reports have demonstrated that salvage chemotherapy followed by ASCT are feasible in select subgroups of elderly patients. [21] [22] [23] Older adults (465 years) comprised 23% (n = 16) of TECAM patients and 8% (n = 6) of BEAM patients. Median OS for these patients was 47 month TECAM and 34 months BEAM, which corresponds to previous series. 21, 24 Interestingly, older age was not associated with a shorter survival or worse outcomes in any of the analyses. These results differ from a large series from the EBMT which reported worse outcomes with BEAM in patients over the age of 60 years compared to younger subjects. 25 Although the small sample size does not allow drawing strong conclusions, it is possible that TECAM, which was perceived by our team as a lower toxicity regimen (compared to BEAM) and was therefore the main regimen used for older patients, can overcome the worse outcomes associated with ASCT in older age.
Our study has several limitations that extend beyond its retrospective single center nature. First, though not statistically significant there was a difference in PFS and OS between the TECAM and BEAM groups which might have become more pronounced with a larger more homogenous cohort. Notwithstanding, our findings are supported by similar observations with the TEAM regimen which is very similar to TECAM (higher doses of thiotepa omitting cyclophosphamide). 9 In this regard, it should also be noted that TECAM patients had a longer time from diagnosis and a higher rate of CR at transplant, possibly representing a more responsive disease. Conversely, TECAM patients were over a decade older, and were probably frailer and with more prior lines of therapies. Thus, it is impossible to Figure 2 . Overall survival by conditioning regimen. Thiotepa-cyclophosphamide-EAM vs BEAM for ASCTdraw strong conclusions from our observations and they should be considered as hypothesis generating only. With limitations of sample size and patient heterogeneity, TECAM conditioning had comparable efficacy and safety profiles to that of BEAM and possibly an advantage in older patients. These observations provide further support to the evidence that thiotepa-based regimens provide an alternative for patients in whom there is a concern of carmustine toxicities. Considering the similarity of results to TEAM it is possible that cyclophosphamide can be omitted with little effect on efficacy.
